Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Double-Blind, Placebo-Controlled, Randomised, First in Human, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of NYR-BI03 in Healthy Participants, When Administered as an Infusion for up to 6 Hours

NCT06894862 is registered in ClinicalTrials.gov with Nyrada Pty Ltd as lead sponsor.

NCT NCT06894862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06894862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Double-Blind, Placebo-Controlled, Randomised, First in Human, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of NYR-BI03 in Healthy Participants, When Administered as an Infusion for up to 6 Hours
Lead sponsor
Nyrada Pty Ltd
Phase
Phase 1
Overall status
Completed
Start date
March 19, 2025
Completion date
July 25, 2025
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy